Inmagene’s anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
Article Date
August 18, 2023
This article is featured on another website.
Go to article
January 29, 2026
Successful Rescue and Transition of a Phase I Oncology Study for a US Biotech Company
Overview A US biotech company's Phase I oncology study had stalled under the management of…
January 29, 2026
Successful Rescue and Transition of a Phase I Oncology Study for a US Biotech Company
Overview A US biotech company's Phase I oncology study had stalled under the management of…